Ruffer LLP Takes $15.15 Million Position in Solventum Corporation $SOLV

Ruffer LLP purchased a new position in shares of Solventum Corporation (NYSE:SOLV) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 207,557 shares of the company’s stock, valued at approximately $15,152,000.

Other large investors have also recently modified their holdings of the company. Deseret Mutual Benefit Administrators increased its stake in Solventum by 78.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after purchasing an additional 163 shares during the period. CYBER HORNET ETFs LLC bought a new position in Solventum in the second quarter worth $28,000. Barrett & Company Inc. lifted its holdings in shares of Solventum by 206.2% during the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after purchasing an additional 268 shares during the last quarter. IMG Wealth Management Inc. bought a new position in shares of Solventum during the second quarter valued at $31,000. Finally, MUFG Securities EMEA plc purchased a new stake in shares of Solventum during the second quarter valued at approximately $31,000.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. KeyCorp raised Solventum from a “sector weight” rating to an “overweight” rating and set a $97.00 target price on the stock in a report on Monday. Stifel Nicolaus upped their target price on shares of Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Wall Street Zen raised shares of Solventum from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Zacks Research lowered Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Finally, BTIG Research raised Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a research note on Tuesday, December 2nd. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $90.83.

Solventum Trading Down 1.3%

Solventum stock opened at $76.60 on Thursday. The company has a market capitalization of $13.29 billion, a price-to-earnings ratio of 8.83, a price-to-earnings-growth ratio of 7.12 and a beta of 0.34. Solventum Corporation has a 52 week low of $60.70 and a 52 week high of $88.20. The stock has a 50-day moving average price of $81.70 and a 200 day moving average price of $75.78. The company has a quick ratio of 1.14, a current ratio of 1.50 and a debt-to-equity ratio of 1.03.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.43 by $0.07. The company had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.Solventum’s quarterly revenue was up .7% on a year-over-year basis. During the same period last year, the business earned $1.64 earnings per share. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Sell-side analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Solventum declared that its Board of Directors has approved a share repurchase plan on Thursday, November 20th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to repurchase up to 7.5% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.